A company has received its PLI approval and the eligibility certificate has been issued. What is the timeline and institutional journey before the first rupee of the incentive is actually realised, and why is the distance between approval and disbursement one of the least understood dimensions of India's incentive architecture?
The verification and disbursement architecture that sits between approval and payment is where most of the operational distance in India's incentive schemes is actually covered. An incentive scheme is announced with ambitious targets and generous outlays; the eligibility criteria are published, applications are invited, and approvals are granted. But the distance between approval and actual disbursement is where most organisations encounter friction. Incentive realisation requires a separate set of administrative actions: verification of claims, submission of utilisation certificates, audit clearance, and, in many cases, resolution of definitional ambiguities that only surface at the disbursement stage.
A company may be approved under a PLI scheme but find that its actual production figures, as calculated by the implementing ministry, differ from its own calculations due to differing interpretations of "incremental production" or "eligible investment." The resolution of such interpretive disputes can take months; and the disbursement is held until the matter is settled. Eligibility is not outcome. Approval is not disbursement.
The money in the account is the only metric that matters. By December 2025, total incentive disbursements across all 14 PLI schemes stood at approximately ₹28,748 crore, roughly 15% of the ₹1.97 lakh crore cumulative outlay. This does not indicate scheme-level shortfall; it reflects the phased nature of production targets that ramp up over time. But it confirms the structural observation: the distance between budget allocation and actual disbursement is measured in years, and the regulatory journey from approval to that point is where most advisory arrangements lack the operational depth to follow through.
The verification architecture that sits between approval and disbursement is specific and institutionally layered. Consider the PLI Scheme for Bulk Drugs. IFCI Limited serves as the Project Management Agency (PMA). When a company files an incentive claim, the PMA verifies the details of sales and investment based on documents submitted by the company, including a statutory auditor's certificate and a chartered engineer's certificate. The PMA then undertakes an independent field visit to the manufacturing site, checking production data against the documents submitted. The incentive is not calculated on the company's reported sales value. It is calculated using the lower of the Quoted Sale Price (QSP), a benchmark established under the scheme, and either the actual selling price or the cost of production, depending on the product segment. Whichever is lower becomes the basis for calculating the incentive. The company cannot inflate its sale price to increase the incentive quantum.
This creates a structural mismatch between what companies project and what the scheme actually pays. A company's finance team typically models incentive income based on its actual selling price. The PMA calculates it based on the lower of the selling price and the QSP benchmark. If the selling price exceeds the benchmark, the difference is money the company has projected but the scheme will never disburse. This single mechanism explains a significant portion of the distance between expected and actual incentive realisation across PLI schemes. The Meghmani LLP claim for Para Amino Phenol illustrates the arithmetic precisely. The company yielded 6,690 MT. The Quoted Sale Price benchmark was ₹55 per kg. The cost of production was ₹260 per kg. The scheme calculated eligible sales using the lower of the two: ₹55 per kg, not ₹260.
The resulting eligible sales figure was ₹36.8 crore, and the incentive recommended at 10% was ₹3.68 crore. A company whose finance team modelled the incentive against cost of production would have projected a figure nearly five times higher. The scheme paid against the benchmark, not against the company's own numbers.
Only after this verification does the PMA recommend the incentive to the Empowered Committee, chaired by the CEO of NITI Aayog (National Institution for Transforming India), which approves or raises further queries before disbursement is sanctioned.
Each of these steps is a distinct institutional checkpoint. Meghmani LLP's incentive claim for Para Amino Phenol, for which it had committed ₹55.06 crore in investment and delivered ₹59.21 crore, yielded an approved incentive of ₹3.68 crore after the full PMA verification cycle. Centrient Pharmaceuticals India's claim for Atorvastatin, processed in two half-yearly tranches, required separate PMA verification for each period. Dasami Lab Private Limited's first incentive claim was initially submitted without the requisite statutory auditor's and chartered engineer's certificates; it could not be processed until those certificates were provided. The verification is not a formality. It is the institutional mechanism through which the government ensures that public money flows only against verified production, verified investment, and verified domestic value addition.
A further layer emerges when scheme participants outperform their individual ceilings. When a company's incremental sales exceed the ceiling prescribed by the scheme, the additional incentive cannot be automatically disbursed. It must wait for an institutional decision on whether the savings from underperforming participants can be redistributed. The Empowered Committee for the PLI for Large Scale Electronics Manufacturing constituted a separate committee to prepare a report on "Unappropriated Incentive/Savings resulting from underperformance of applicants under PLI scheme." Until that committee completes its evaluation, the outperforming company's additional incentive remains pending. The company's performance has exceeded expectations. The institutional mechanism for recognising that performance has not yet been created. This is the distance between eligibility and disbursement in its most precise form. The companies that budget for this distance, in time, in compliance resources, and in institutional engagement, are the ones that eventually collect.
The three-layer certification stack underneath the PMA's review is the dimension most applicants configure their compliance function around least well. The Statutory Auditor certifies incremental sales and incremental investment against the defined base year; an independent Chartered Accountant, in most electronics and IT Hardware schemes, certifies the Domestic Value Addition computation as a separate exercise; the PMA then conducts its own review of both certifications, raises written queries, and undertakes a physical verification of the manufacturing premises before recommending disbursement to the implementing ministry. Each of these three layers can return the file for rework, and most beneficiaries underestimate how frequently the PMA does so. A compliance architecture built for the Statutory Auditor's certification alone will not survive the PMA's verification cycle, because the PMA's evaluation template reflects the documentation gaps that previous schemes revealed, and the documentation depth required is calibrated against those learnings rather than against what is commercially convenient to assemble.
The DVA claim is only as reliable as the weakest first-tier supplier's paper trail. The operational guideline prescribes the DVA calculation at the product level, not the factory level, and the computation is conducted through the bill of materials with attribution rules that must trace indigenous content to its manufacturing origin. A domestic vendor that is itself a trader, aggregating imports and reselling to the beneficiary as indigenous content, drops through the attribution at the PMA's stress test. The applicant carries the burden of demonstrating the supplier's own manufacturing record, which the supplier is often neither contractually bound nor commercially willing to disclose. Procurement contracts that do not embed the DVA paper-trail obligation at purchase order stage generate audit exposure at the claim stage that the applicant cannot cure without renegotiating the supplier relationship, by which time the claim cycle has already moved.
Operational guideline drift is the least visible and most consequential risk surface. The scheme notification is the statutory instrument, but the operational guidelines are where the compliance detail lives, and they are amended through office memoranda issued by the implementing ministry without the public communication that accompanies the original notification. A company that configured its internal compliance and ERP against OG version 1.3 in year one may find in year three that OG version 2.1 has redefined which sub-assemblies count toward DVA, or shifted the base year treatment for incremental production. The beneficiary is deemed to have notice of the current OG; ignorance of a revision does not preserve a prior computation. A quiet discipline of tracking every OG amendment and rebuilding the compliance model against each revision is what separates the claims that clear from the ones that sit.
The clawback surface runs wider than most applicants price. Missed investment thresholds in any claim year disqualify the beneficiary for that year's incentive and can trigger rescrutiny of prior-year claims under certain schemes. Material misrepresentation in DVA or incremental production is treated as fraud and can result in recovery with interest, blacklisting from future central schemes, and in severe cases referral for prosecution. A change of control that is not notified to and approved by the implementing agency is a disqualifying event in most scheme architectures; some notifications treat it as triggering refund of prior disbursements. The product category exiting the eligible basket mid-cycle, which has occurred in past PLI iterations when HS codes were reorganised, leaves the beneficiary with a stranded compliance cost and no disbursement path. Private equity and venture capital investors acquiring stakes in scheme beneficiaries routinely encounter the change-of-control clause as a transaction condition; exit from the scheme before its notified service period, whether through restructuring, divestment, or facility closure, carries refund-with-interest liability that must be priced into the exit waterfall before the transaction closes.
Disbursement timing is the variable the scheme dashboards do not display. From a clean claim filing to credit in the applicant's account, nine to eighteen months is the realistic range across most schemes in steady state. The first three to four months are absorbed by PMA review and query cycles. The next two to four months sit in the implementing ministry's internal approval architecture, which routes through the Financial Advisor and the expenditure finance committee layer depending on disbursement size. The final phase, release by the Integrated Finance Division and actual credit through Public Financial Management System channels, is itself a two to three month window that rarely compresses regardless of applicant urgency. A company that has modelled its cash flow against annual disbursement is carrying working capital for at least one year of delay against that assumption, and a company that has not modelled the delay at all is financing the working capital at its own cost of capital while waiting for the scheme's cost of capital to release.